With analysts predicting a surge in business spending on AI to reach $300 billion by 2026, it is becoming increasingly clear that the transformative power of AI will also have major implications for the future of healthcare and the wider pharmaceutical industry.
There is huge potential in the ability of AI to help streamline and quicken the processes involved in the running of clinical trials.
From trial design to monitoring, the potential here for better ecosystem integration cannot be overstated. General efficacy, efficiency and designing bespoke fit for purpose trials will all be greatly improved thanks to AI.
Check out the rest of the feature here
